Physician profile
Gul Madison
NPI 1194844001
$5,435.41
in general payments reported to CMS, 2019-2025
13 companies · $692 in 2025
The $692 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $792 · 2021: $541 · 2022: $1,033 · 2023: $1,105 · 2024: $720 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.42 |
| Education | $117.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,763.16 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Insmed, INC. | $810.27 | 2019-2024 | Arikayce |
| Gilead Sciences, INC. | $804.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $761.69 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $429.48 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $332.76 | 2022-2025 | Trogarzo, Egrifta |
| Melinta Therapeutics, LLC | $165.27 | 2019-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $91.22 | 2022-2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $84.97 | 2023-2025 | Vowst |
| Shionogi INC | $80.96 | 2023-2024 | Fetroja |
| Janssen Pharmaceuticals, INC | $44.15 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $41.52 | 2025 | Zevtera, Xacduro |
| Abbvie INC. | $24.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gul Madison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.